Advertisement
New Zealand markets closed

  • NZX 50

    12,349.47
    -46.80 (-0.38%)
     

  • NZD/USD

    0.5890
    +0.0001 (+0.01%)
     

  • NZD/EUR

    0.5417
    -0.0009 (-0.16%)
     

  • ALL ORDS

    8,153.40
    +59.10 (+0.73%)
     

  • ASX 200

    7,921.30
    +60.10 (+0.76%)
     

  • OIL

    76.44
    -1.84 (-2.35%)
     

  • GOLD

    2,385.70
    +32.20 (+1.37%)
     

  • NASDAQ

    19,023.66
    +193.07 (+1.03%)
     

  • FTSE

    8,285.71
    +99.36 (+1.21%)
     

  • Dow Jones

    40,589.34
    +654.27 (+1.64%)
     

  • DAX

    18,417.55
    +118.83 (+0.65%)
     

  • Hang Seng

    17,021.31
    +16.34 (+0.10%)
     

  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     

  • NZD/JPY

    90.5250
    -0.0680 (-0.08%)
     

Why Pfizer Stock Crushed the Market on Monday

Eric Volkman, The Motley Fool
·1-min read
Why Pfizer Stock Crushed the Market on Monday

The holy grail of pharmaceutical companies and biotechs is the development of a medication with blockbuster potential, and Pfizer seems to have one on its hands. A peer-reviewed study of Pfizer's investigational drug danuglipron found that the medication lowered both blood sugar and body weight after 16 weeks of use when compared to a placebo. Compounding that, that level of weight loss is comparable to pharmaceutical rival Novo Nordisk's (NYSE: NVO) highly successful semaglutide, a commercialized drug known in this country as either Ozempic or Rybelsus for diabetes, and Wegovy for weight loss.

Continue reading